Pre-market hot trades in US stocks: Waldencast pre-market down 8.33%; Royalty pre-market up 7.32%

Pre-market Hot Trades in US Stocks

Waldencast is down 8.33% in pre-market trading. Based on recent key news:

1. On November 24, Waldencast reported a second-quarter adjusted EBITDA of $3.3 million, a year-on-year decrease of 47.3%. Although net income increased by 5.6% year-on-year to $66.8 million, net income for the third quarter fell by 3.4% year-on-year to $67.8 million, raising market concerns about the company's profitability and putting pressure on the stock price. Source: Reuters

2. On November 24, the company updated its fiscal year 2025 guidance, expecting net income to remain flat compared to 2024, with an adjusted EBITDA margin in the high single digits. The company anticipates limited growth in commodity costs and will respond to changes in the tariff environment through necessary price adjustments, but this news failed to boost market confidence. Source: Reuters

3. On November 25, Canaccord Genuity analyst Susan Anderson maintained a buy rating on Waldencast with a target price of $4. Despite the analyst's optimistic view of the company, the market remains skeptical about its short-term performance. Source: TipRanks The consumer goods industry faces challenges in the international market.

Royalty is up 7.32% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Top Gainers in Pre-market US Stocks

Rubico is up 41.91% in pre-market trading. Based on recent key news:

1. On November 25, Rubico announced an agreement with its regular charterer to extend the lease. This news indicates enhanced stability in the company's business, driving the stock price up 41.91% in pre-market trading. Source: Globe Newswire The tanker industry is experiencing increased demand, and the market is active.

Kohl's is up 28.39% in pre-market trading. Based on recent key news:

1. On November 25, Kohl's reported better-than-expected third-quarter earnings and raised its full-year guidance. The earnings report showed a year-on-year sales decline of 2.8% to $3.41 billion, but it exceeded analyst expectations, driving the stock price up approximately 27% in pre-market trading. Source: Zhito Finance

2. On November 24, Michael Bender was appointed as the official CEO of Kohl's, succeeding the former CEO who left due to personal relationship issues. This move is seen as an important step for the company to get back on track, boosting the stock price. Source: Zhito Finance

3. On November 25, Kohl's projected a significant increase in adjusted earnings per share for fiscal year 2025 to $1.25-$1.45, demonstrating the company's confidence in future performance and further driving the stock price up. Source: Reuters The retail industry faces reduced consumer spending, and Kohl's offers affordable pricing Clearmind Medicine pre-market rose 26.20%. Based on recent key news:

4. On November 24, Clearmind Medicine announced the recruitment of its first patient at a leading research site in Israel, accelerating the enrollment process for its global study. This progress has enhanced market confidence in the company's clinical trial success, driving up the stock price.

5. On November 24, Clearmind Medicine released news through GlobeNewswire, emphasizing its progress in the development of novel neuroplasticity drugs. This news has raised investors' expectations for the company's future growth potential, further boosting the stock price.

6. On November 25, Clearmind Medicine reiterated its commitment to forward-looking statements in a press release. Although no specific updates were provided, the market's recognition of the company's transparency has also supported the stock price. The biotechnology sector has been active recently, attracting high investor attention